Long-Term Outcomes of Patients With Late Presentation of ST-Segment Elevation Myocardial Infarction
Kyung Hoon Cho1, Xiongyi Han1, Joon Ho Ahn1
1Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
Insights
Patients with ST-elevation myocardial infarction (STEMI) presenting late (12-48 hours) had worse outcomes and less intervention. A multidisciplinary approach is needed for these STEMI patients.
Area of Science:
- Cardiology
- Clinical Research
- Public Health
Background:
- Limited real-world data exists on late presenters (12-48 hours) of ST-segment elevation myocardial infarction (STEMI).
- Understanding baseline characteristics, clinical practice, and outcomes of STEMI late presenters is crucial.
Purpose of the Study:
- To investigate the real-world features of STEMI late presenters in the current percutaneous coronary intervention (PCI) era.
- To compare outcomes between early (<12 hours) and late (12-48 hours) STEMI presenters.
Main Methods:
- Analysis of 5,826 STEMI patients from the Korea Acute Myocardial Infarction Registry-National Institutes of Health database (2011-2015).
- Patients were categorized into early (<12 hours) and late (12-48 hours) presenters.
- Coprimary outcomes included 180-day and 3-year all-cause mortality.
Main Results:
- Late presenters (n=624) exhibited significantly worse clinical outcomes than early presenters (n=5,202).
- 180-day mortality was 10.7% for late vs. 6.8% for early presenters (p<0.001); 3-year mortality was 16.2% vs. 10.6% (p<0.001).
- Use of invasive procedures decreased, and mortality rates increased significantly in the 12-24 hour interval compared to <12 hours.
Conclusions:
- Nationwide data shows stark differences in intervention use and mortality between early and late STEMI presenters.
- A multidisciplinary approach is necessary to identify late STEMI presenters who could benefit from invasive procedures.
Background:
Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in patients with ST-segment elevation myocardial infarction (STEMI) are limited.
Objectives:
This study aimed to investigate real-world features of STEMI late presenters in the contemporary percutaneous coronary intervention (PCI) era.
Methods:
Of 13,707 patients from the Korea Acute Myocardial Infarction Registry-National Institutes of Health database, 5,826 consecutive patients diagnosed with STEMI within 48 h of symptom onset during 2011 to 2015 were categorized as late (12 to 48 h; n = 624) or early (<12 h; n = 5,202) presenters. Coprimary outcomes were 180-day and 3-year all-cause mortality.
Results:
Late presenters had remarkably worse clinical outcomes than early presenters (180-day mortality: 10.7% vs. 6.8%; 3-year mortality: 16.2% vs. 10.6%; both log-rank p < 0.001), whereas presentation at ≥12 h of symptom onset was not independently associated with increased mortality after STEMI. The use of invasive interventional procedures abruptly decreased from the first (<12 h) to the second (12 to 24 h) 12-h interval of symptom-to-door time ("no primary PCI strategy" increased from 4.9% to 12.4%, and "no PCI" from 2.3% to 6.6%; both p < 0.001). Mortality rates abruptly increased from the first to the second 12-h interval of symptom-to-door time (from 6.8% to 11.2% for 180-day mortality; from 10.6% to 17.3% for 3-year mortality; all p < 0.05).
Conclusions:
Data from a nationwide prospective Korean registry reveal that inverse steep differences in the use of invasive interventional procedures and mortality rates were found between early and late presenters after STEMI. A multidisciplinary approach is required in identifying late presenters of STEMI who can benefit from invasive interventional procedures until further studied.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome IV: Interprofessional Care
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Endocarditis III: Medical Management
